U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6O4
Molecular Weight 142.1094
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KOJIC ACID

SMILES

OCC1=CC(=O)C(O)=CO1

InChI

InChIKey=BEJNERDRQOWKJM-UHFFFAOYSA-N
InChI=1S/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2

HIDE SMILES / InChI

Molecular Formula C6H6O4
Molecular Weight 142.1094
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Kojic acid was first discovered in Japan in 1907. Kojic acid is a chelation agent produced by several species of fungi, especially Aspergillus oryzae, which has the Japanese common name koji. Kojic acid is a by-product in the fermentation process of malting rice, for use in the manufacturing of sake, the Japanese rice wine. It is a mild inhibitor of the formation of pigment in plant and animal tissues, and is used in food and cosmetics to preserve or change colors of substances. It forms a bright red complex with ferric ions. Kojic acid may be used on cut fruits to prevent oxidative browning, in seafood to preserve pink and red colors, and in cosmetics. In skin care products, kojic acid functions primarily as a skin-lightening agent. It is a potent tyrosinase inhibitor. It penetrates the upper skin layers and inhibits the production of epidermal melanin. As an example of the latter, it is used to treat skin diseases like melasma. Kojic acid also has antibacterial and antifungal properties. The cocrystals of kojic acid with quercetin were found to have two times better cytotoxic activity to human cervical cancer cells (HeLa) and human colon cancer cells (Caco-2) in comparison with quercetin itself.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
7.4 µM [IC50]
2.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Topical formulation
Route of Administration: Topical
In Vitro Use Guide
Kojic acid inhibited human tyrosinase activity with an IC(50) 500 umol/L.
Substance Class Chemical
Record UNII
6K23F1TT52
Record Status Validated (UNII)
Record Version